The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Non Hodgkin Lymphoma (NHL) Market Research Report 2025
Synopsis
Non-Hodgkin Lymphoma is the most common lymphoma which affects large number of people. It begins in lymphocytes present in lymph nodes of body parts such as neck or chest or under the arms. It widely spreads to the other lymph nodes and to other organs such as bone marrow, lungs, or liver.
The global Non Hodgkin Lymphoma (NHL) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Non Hodgkin Lymphoma (NHL) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Non Hodgkin Lymphoma (NHL) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Non Hodgkin Lymphoma (NHL) in Hosptial is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Non Hodgkin Lymphoma (NHL) include F. Hoffmann-La Roche, Johnson & Johnson, Merck, Bristol Myers Squibb, Celgene, Eli Lilly, GlaxoSmithKline and Bayer, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Non Hodgkin Lymphoma (NHL), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non Hodgkin Lymphoma (NHL).
Report Scope
The Non Hodgkin Lymphoma (NHL) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Non Hodgkin Lymphoma (NHL) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Non Hodgkin Lymphoma (NHL) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
F. Hoffmann-La Roche
Johnson & Johnson
Merck
Bristol Myers Squibb
Celgene
Eli Lilly
GlaxoSmithKline
Bayer
Segment by Type
Standard
Exellent
Segment by Application
Hosptial
Clinic
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Non Hodgkin Lymphoma (NHL) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Non-Hodgkin Lymphoma is the most common lymphoma which affects large number of people. It begins in lymphocytes present in lymph nodes of body parts such as neck or chest or under the arms. It widely spreads to the other lymph nodes and to other organs such as bone marrow, lungs, or liver.
The global Non Hodgkin Lymphoma (NHL) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Non Hodgkin Lymphoma (NHL) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Non Hodgkin Lymphoma (NHL) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Non Hodgkin Lymphoma (NHL) in Hosptial is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Non Hodgkin Lymphoma (NHL) include F. Hoffmann-La Roche, Johnson & Johnson, Merck, Bristol Myers Squibb, Celgene, Eli Lilly, GlaxoSmithKline and Bayer, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Non Hodgkin Lymphoma (NHL), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non Hodgkin Lymphoma (NHL).
Report Scope
The Non Hodgkin Lymphoma (NHL) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Non Hodgkin Lymphoma (NHL) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Non Hodgkin Lymphoma (NHL) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
F. Hoffmann-La Roche
Johnson & Johnson
Merck
Bristol Myers Squibb
Celgene
Eli Lilly
GlaxoSmithKline
Bayer
Segment by Type
Standard
Exellent
Segment by Application
Hosptial
Clinic
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Non Hodgkin Lymphoma (NHL) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Non Hodgkin Lymphoma (NHL) Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Standard
1.2.3 Exellent
1.3 Market by Application
1.3.1 Global Non Hodgkin Lymphoma (NHL) Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hosptial
1.3.3 Clinic
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Non Hodgkin Lymphoma (NHL) Market Perspective (2019-2030)
2.2 Non Hodgkin Lymphoma (NHL) Growth Trends by Region
2.2.1 Global Non Hodgkin Lymphoma (NHL) Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Non Hodgkin Lymphoma (NHL) Historic Market Size by Region (2019-2024)
2.2.3 Non Hodgkin Lymphoma (NHL) Forecasted Market Size by Region (2025-2030)
2.3 Non Hodgkin Lymphoma (NHL) Market Dynamics
2.3.1 Non Hodgkin Lymphoma (NHL) Industry Trends
2.3.2 Non Hodgkin Lymphoma (NHL) Market Drivers
2.3.3 Non Hodgkin Lymphoma (NHL) Market Challenges
2.3.4 Non Hodgkin Lymphoma (NHL) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Non Hodgkin Lymphoma (NHL) Players by Revenue
3.1.1 Global Top Non Hodgkin Lymphoma (NHL) Players by Revenue (2019-2024)
3.1.2 Global Non Hodgkin Lymphoma (NHL) Revenue Market Share by Players (2019-2024)
3.2 Global Non Hodgkin Lymphoma (NHL) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Non Hodgkin Lymphoma (NHL) Revenue
3.4 Global Non Hodgkin Lymphoma (NHL) Market Concentration Ratio
3.4.1 Global Non Hodgkin Lymphoma (NHL) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Non Hodgkin Lymphoma (NHL) Revenue in 2023
3.5 Non Hodgkin Lymphoma (NHL) Key Players Head office and Area Served
3.6 Key Players Non Hodgkin Lymphoma (NHL) Product Solution and Service
3.7 Date of Enter into Non Hodgkin Lymphoma (NHL) Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Non Hodgkin Lymphoma (NHL) Breakdown Data by Type
4.1 Global Non Hodgkin Lymphoma (NHL) Historic Market Size by Type (2019-2024)
4.2 Global Non Hodgkin Lymphoma (NHL) Forecasted Market Size by Type (2025-2030)
5 Non Hodgkin Lymphoma (NHL) Breakdown Data by Application
5.1 Global Non Hodgkin Lymphoma (NHL) Historic Market Size by Application (2019-2024)
5.2 Global Non Hodgkin Lymphoma (NHL) Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Non Hodgkin Lymphoma (NHL) Market Size (2019-2030)
6.2 North America Non Hodgkin Lymphoma (NHL) Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Non Hodgkin Lymphoma (NHL) Market Size by Country (2019-2024)
6.4 North America Non Hodgkin Lymphoma (NHL) Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Non Hodgkin Lymphoma (NHL) Market Size (2019-2030)
7.2 Europe Non Hodgkin Lymphoma (NHL) Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Non Hodgkin Lymphoma (NHL) Market Size by Country (2019-2024)
7.4 Europe Non Hodgkin Lymphoma (NHL) Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Non Hodgkin Lymphoma (NHL) Market Size (2019-2030)
8.2 Asia-Pacific Non Hodgkin Lymphoma (NHL) Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Non Hodgkin Lymphoma (NHL) Market Size by Region (2019-2024)
8.4 Asia-Pacific Non Hodgkin Lymphoma (NHL) Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Non Hodgkin Lymphoma (NHL) Market Size (2019-2030)
9.2 Latin America Non Hodgkin Lymphoma (NHL) Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Non Hodgkin Lymphoma (NHL) Market Size by Country (2019-2024)
9.4 Latin America Non Hodgkin Lymphoma (NHL) Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Non Hodgkin Lymphoma (NHL) Market Size (2019-2030)
10.2 Middle East & Africa Non Hodgkin Lymphoma (NHL) Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Non Hodgkin Lymphoma (NHL) Market Size by Country (2019-2024)
10.4 Middle East & Africa Non Hodgkin Lymphoma (NHL) Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 F. Hoffmann-La Roche
11.1.1 F. Hoffmann-La Roche Company Detail
11.1.2 F. Hoffmann-La Roche Business Overview
11.1.3 F. Hoffmann-La Roche Non Hodgkin Lymphoma (NHL) Introduction
11.1.4 F. Hoffmann-La Roche Revenue in Non Hodgkin Lymphoma (NHL) Business (2019-2024)
11.1.5 F. Hoffmann-La Roche Recent Development
11.2 Johnson & Johnson
11.2.1 Johnson & Johnson Company Detail
11.2.2 Johnson & Johnson Business Overview
11.2.3 Johnson & Johnson Non Hodgkin Lymphoma (NHL) Introduction
11.2.4 Johnson & Johnson Revenue in Non Hodgkin Lymphoma (NHL) Business (2019-2024)
11.2.5 Johnson & Johnson Recent Development
11.3 Merck
11.3.1 Merck Company Detail
11.3.2 Merck Business Overview
11.3.3 Merck Non Hodgkin Lymphoma (NHL) Introduction
11.3.4 Merck Revenue in Non Hodgkin Lymphoma (NHL) Business (2019-2024)
11.3.5 Merck Recent Development
11.4 Bristol Myers Squibb
11.4.1 Bristol Myers Squibb Company Detail
11.4.2 Bristol Myers Squibb Business Overview
11.4.3 Bristol Myers Squibb Non Hodgkin Lymphoma (NHL) Introduction
11.4.4 Bristol Myers Squibb Revenue in Non Hodgkin Lymphoma (NHL) Business (2019-2024)
11.4.5 Bristol Myers Squibb Recent Development
11.5 Celgene
11.5.1 Celgene Company Detail
11.5.2 Celgene Business Overview
11.5.3 Celgene Non Hodgkin Lymphoma (NHL) Introduction
11.5.4 Celgene Revenue in Non Hodgkin Lymphoma (NHL) Business (2019-2024)
11.5.5 Celgene Recent Development
11.6 Eli Lilly
11.6.1 Eli Lilly Company Detail
11.6.2 Eli Lilly Business Overview
11.6.3 Eli Lilly Non Hodgkin Lymphoma (NHL) Introduction
11.6.4 Eli Lilly Revenue in Non Hodgkin Lymphoma (NHL) Business (2019-2024)
11.6.5 Eli Lilly Recent Development
11.7 GlaxoSmithKline
11.7.1 GlaxoSmithKline Company Detail
11.7.2 GlaxoSmithKline Business Overview
11.7.3 GlaxoSmithKline Non Hodgkin Lymphoma (NHL) Introduction
11.7.4 GlaxoSmithKline Revenue in Non Hodgkin Lymphoma (NHL) Business (2019-2024)
11.7.5 GlaxoSmithKline Recent Development
11.8 Bayer
11.8.1 Bayer Company Detail
11.8.2 Bayer Business Overview
11.8.3 Bayer Non Hodgkin Lymphoma (NHL) Introduction
11.8.4 Bayer Revenue in Non Hodgkin Lymphoma (NHL) Business (2019-2024)
11.8.5 Bayer Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
